For the past 54 years, the Canadian Neurological Sciences Federation (CNSF) has held an annual meeting that features presentations on advances in neurology.
The CARE™ Faculty focuses on key news framed from a Canadian perspective in multiple disease categories, including advancements in the field of neurology and the chronic disease known as Myasthenia Gravis (MG).
This year, there was exciting news presented at the CNSF meeting on the management of MG, much of which was based on updates from the REGAIN study or its associated open label extension.
This report covers:
- Interim data from the REGAIN study open label extension
- MG-ADL, QMG, MGC, and MG-QoL15 evaluations of REGAIN patients with prior IVIg
- Long-term exacerbation rates in the REGAIN population